Stephane Bancel - 01 Mar 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MRNA
Reported as of: 01 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:19:47 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ James Dillon, as Attorney-in-Fact

Key filing fact

Stephane Bancel filed Form 4 for Moderna, Inc. (MRNA) on 03 Mar 2026.

Key facts

This page summarizes Stephane Bancel's Form 4 filing for Moderna, Inc. (MRNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:19.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001443340 Primary reporting owner

Bancel Stephane

Relationship: Chief Executive Officer, Director
Address: C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
Signature: /s/ James Dillon, as Attorney-in-Fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,187,791
Date: 01 Mar 2026
Ownership: Direct

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 9,210,686
Date: 01 Mar 2026
Ownership: See Footnote
Footnotes: F1

MRNA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 6,564,880
Date: 01 Mar 2026
Ownership: See Footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MRNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +250,932
Change %
Price: $0.000000
Shares after: 250,932
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,932
Exercise price: $53.57
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F2

These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F3

25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.